These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 25249180)

  • 1. The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor.
    Gosmini R; Nguyen VL; Toum J; Simon C; Brusq JM; Krysa G; Mirguet O; Riou-Eymard AM; Boursier EV; Trottet L; Bamborough P; Clark H; Chung CW; Cutler L; Demont EH; Kaur R; Lewis AJ; Schilling MB; Soden PE; Taylor S; Walker AL; Walker MD; Prinjha RK; Nicodème E
    J Med Chem; 2014 Oct; 57(19):8111-31. PubMed ID: 25249180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
    Mirguet O; Gosmini R; Toum J; Clément CA; Barnathan M; Brusq JM; Mordaunt JE; Grimes RM; Crowe M; Pineau O; Ajakane M; Daugan A; Jeffrey P; Cutler L; Haynes AC; Smithers NN; Chung CW; Bamborough P; Uings IJ; Lewis A; Witherington J; Parr N; Prinjha RK; Nicodème E
    J Med Chem; 2013 Oct; 56(19):7501-15. PubMed ID: 24015967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.
    Mirguet O; Lamotte Y; Donche F; Toum J; Gellibert F; Bouillot A; Gosmini R; Nguyen VL; Delannée D; Seal J; Blandel F; Boullay AB; Boursier E; Martin S; Brusq JM; Krysa G; Riou A; Tellier R; Costaz A; Huet P; Dudit Y; Trottet L; Kirilovsky J; Nicodeme E
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2963-7. PubMed ID: 22386529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
    Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
    J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Benzo[
    Jiang F; Hu Q; Zhang Z; Li H; Li H; Zhang D; Li H; Ma Y; Xu J; Chen H; Cui Y; Zhi Y; Zhang Y; Xu J; Zhu J; Lu T; Chen Y
    J Med Chem; 2019 Dec; 62(24):11080-11107. PubMed ID: 31789032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naphthyridines as novel BET family bromodomain inhibitors.
    Mirguet O; Lamotte Y; Chung CW; Bamborough P; Delannée D; Bouillot A; Gellibert F; Krysa G; Lewis A; Witherington J; Huet P; Dudit Y; Trottet L; Nicodeme E
    ChemMedChem; 2014 Mar; 9(3):580-9. PubMed ID: 24000170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.
    Xue X; Zhang Y; Liu Z; Song M; Xing Y; Xiang Q; Wang Z; Tu Z; Zhou Y; Ding K; Xu Y
    J Med Chem; 2016 Feb; 59(4):1565-79. PubMed ID: 26731490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
    Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
    Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds.
    Chan KH; Zengerle M; Testa A; Ciulli A
    J Med Chem; 2018 Jan; 61(2):504-513. PubMed ID: 28595007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.
    Jones KL; Beaumont DM; Bernard SG; Bit RA; Campbell SP; Chung CW; Cutler L; Demont EH; Dennis K; Gordon L; Gray JR; Haase MV; Lewis AJ; McCleary S; Mitchell DJ; Moore SM; Parr N; Robb OJ; Smithers N; Soden PE; Suckling CJ; Taylor S; Walker AL; Watson RJ; Prinjha RK
    J Med Chem; 2021 Aug; 64(16):12200-12227. PubMed ID: 34387088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains.
    Dittmann A; Werner T; Chung CW; Savitski MM; Fälth Savitski M; Grandi P; Hopf C; Lindon M; Neubauer G; Prinjha RK; Bantscheff M; Drewes G
    ACS Chem Biol; 2014 Feb; 9(2):495-502. PubMed ID: 24533473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery.
    Chung CW; Dean AW; Woolven JM; Bamborough P
    J Med Chem; 2012 Jan; 55(2):576-86. PubMed ID: 22136404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of methyl isoxazoleazepines as inhibitors of BET.
    Hewitt MC; Leblanc Y; Gehling VS; Vaswani RG; Côté A; Nasveschuk CG; Taylor AM; Harmange JC; Audia JE; Pardo E; Cummings R; Joshi S; Sandy P; Mertz JA; Sims RJ; Bergeron L; Bryant BM; Bellon S; Poy F; Jayaram H; Tang Y; Albrecht BK
    Bioorg Med Chem Lett; 2015 May; 25(9):1842-8. PubMed ID: 25851940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
    Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
    Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
    Ran X; Zhao Y; Liu L; Bai L; Yang CY; Zhou B; Meagher JL; Chinnaswamy K; Stuckey JA; Wang S
    J Med Chem; 2015 Jun; 58(12):4927-39. PubMed ID: 26080064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and characterization of small molecule inhibitors of the BET family bromodomains.
    Chung CW; Coste H; White JH; Mirguet O; Wilde J; Gosmini RL; Delves C; Magny SM; Woodward R; Hughes SA; Boursier EV; Flynn H; Bouillot AM; Bamborough P; Brusq JM; Gellibert FJ; Jones EJ; Riou AM; Homes P; Martin SL; Uings IJ; Toum J; Clement CA; Boullay AB; Grimley RL; Blandel FM; Prinjha RK; Lee K; Kirilovsky J; Nicodeme E
    J Med Chem; 2011 Jun; 54(11):3827-38. PubMed ID: 21568322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors.
    Romero FA; Taylor AM; Crawford TD; Tsui V; Côté A; Magnuson S
    J Med Chem; 2016 Feb; 59(4):1271-98. PubMed ID: 26572217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bromodomains: Structure, function and pharmacology of inhibition.
    Ferri E; Petosa C; McKenna CE
    Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
    Fish PV; Filippakopoulos P; Bish G; Brennan PE; Bunnage ME; Cook AS; Federov O; Gerstenberger BS; Jones H; Knapp S; Marsden B; Nocka K; Owen DR; Philpott M; Picaud S; Primiano MJ; Ralph MJ; Sciammetta N; Trzupek JD
    J Med Chem; 2012 Nov; 55(22):9831-7. PubMed ID: 23095041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.
    Bamborough P; Diallo H; Goodacre JD; Gordon L; Lewis A; Seal JT; Wilson DM; Woodrow MD; Chung CW
    J Med Chem; 2012 Jan; 55(2):587-96. PubMed ID: 22136469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.